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In rheumatoid arthritis (RA), the tender and swollen joint counts play a key role 
in the clinical assessment of disease activity, integrating the disease activity score 
(DAS), which is determinant in the treatment decision. However, there is considerable 
variability in these measurements. In this project, we aimed to identify the variables 
influencing the joint counts, and to determine if there was a significant difference in 
these measurements when performed in clinical practice by Rheumatology registrars 
and consultants. For that purpose, we analyzed the possible effect of several variables 
on the joint counts, by analyzing consecutive visits (n=3127) of 260 patients followed 
in a real life setting. We compared the differences in the assessment of disease activity 
parameters between the registrars and consultants using the Student’s T-test. To study 
the impact of each variable in the tender and swollen joint counts, we conducted a 
multivariate analysis using a linear mixed model.  Overall, registrars and consultants 
counted a similar mean number of tender but a higher number of swollen joints 
(1.6±2.8 vs. 2.0±3.7; P-value=0.001). However, when adjusting for other variables, 
neither the training status, nor the years of experience were associated with the joint 
counts. Importantly, variables such as the patient global visual analogue scale (VAS), 
physician VAS and disease duration had a significant impact on both the tender and 
swollen joint counts. Furthermore, the patient’s age was significantly associated with 
the tender joint count. We also found that the inter-observer and inter-patient 
variabilities were both significant, which can be further investigated in studies that 
consider simultaneous assessment of patients by several evaluators. We conclude that 
neither the physician training status nor the years of experience have impact in the 
joint counts, but the disease activity parameters do. 
 









As contagens de articulações dolorosas e tumefactas adquirem um papel 
essencial na avaliação clínica da artrite reumatóide (AR), dado que integram o disease 
activity score (DAS), que é determinante na decisão terapêutica. Contudo, há uma 
variabilidade considerável nestas medições. Neste projecto, definimos como objectivos 
identificar as variáveis que influenciam as contagens articulares, e perceber se há uma 
diferença significativa nestas medições quando estas são realizadas por internos vs. 
especialistas. Para tal, analisámos o possível efeito de várias variáveis com base numa 
amostra de 260 doentes seguidos na prática clínica em consultas consecutivas 
(n=3127). Começámos por fazer uma análise descritiva para caracterizar a amostra, e, 
de seguida, usámos o teste T-Student para perceber se havia diferenças significativas 
entre os internos e os especialistas nos parâmetros de actividade da doença (análise 
univariada). Posteriormente, realizámos uma análise multivariada usando o modelo 
linear misto para estudar o impacte de cada variável nas contagens articulares. Os 
resultados mostraram que os internos e especialistas contaram um número médio de 
articulações dolorosas igual, mas em relação às tumefactas, estes últimos contaram 
valores significativamente mais elevados (1,6±2,8 vs. 2,0±3,7, respectivamente;Valor-
P=0,001). Todavia, ajustando a análise para as restantes variáveis, nem o grau de 
especialidade nem a experiência do médico se revelaram significativamente associados 
às contagens articulares. De notar, tanto a escala visual analógica global do doente 
como a do medico e a duração da doença tiveram impacte significativo nas contagens 
articulares. A idade do doente estava significativamente associada às contagens de 
articulações dolorosas. Por fim, as variabilidades inter-observador e inter-doente 
foram significativas, sendo necessário um estudo de avaliação simultânea dos doentes 
por diferentes médicos para investigar este efeito. Concluindo, nem o grau de 
especialidade do médico nem os anos de experiência se associam às contagens 
articulares, mas os parâmetros de actividade da doença sim. 
 
Palavras-chave: artrite reumatóide, contagens articulares, actividade da 
doença, treino em reumatologia. 
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1 – Background 
 
Rheumatoid Arthritis (RA) is a chronic systemic inflammatory disease mainly 
characterized by joint involvement and progressive destruction over time. Its main 
clinical manifestations are joint tenderness (pain at rest) and swelling, indicating an active 
synovitis process.  
In this context, joint count, which is a clinical method of assessment of disease 
activity, is meant to be an objective parameter, ideally with little inter and intra-assessor 
variability, as it is known to correlate with RA patients’ mortality and prognosis[1]. This 
parameter, along with the patient global visual analogue scale (VAS), C-reactive protein 
(CRP) and erythrocyte sedimentation rate (ESR), integrates the disease activity score 
(DAS; most often DAS28, with 28 joints taken into consideration), which is a validated 
tool to assess disease activity and is crucial in determining the medical course of action: 
a DAS28 greater than 5.1 implies active disease; lower than 3.2, low disease activity and 
lower than 2.6 means remission[2]. Considering the current paradigm of the Treat to 
Target approach – adjusting therapy in order to reach and remain in a low disease activity 
or remission state – joint counts play a central and important role, being an objective 
parameter that ought to have the less variability possible. 
Furthermore, there is a wide range of joint count methods assessing swelling 
and/or tenderness and including different numbers of joints, for a total count of 36[3], 
42[4], 44[5] or even 66/68[6] instead of 28 joints. Comparing the various methods, it was 
concluded[7] that the 28-joint index was not inferior to the others, and has since then been 
the most used in clinical practice and research, considering its simplicity and feasibility. 
However, some issues exist with this approach: most notably the fact the feet joints are 
excluded from disease activity assessment, contributing to misclassification of a subset 
patients that might still present active disease at the level of joints not captured by this 
tool and that are thus at risk of disease progression and disability. 
With this in mind, there is still the issue of inter- and intra-observer variability in 
assessing joint tenderness and swelling, as each medical professional has his/her own set 
of technical skills and personal experience that will have an impact on determining if a 
joint is considered active or not[8]. Moreover, the same assessor will not always reach 
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although this variability has been shown to be acceptable[9]. This reflects the complex 
nature of the very method itself. 
Both bony swelling and joint deformities (which occur essentially with disease 
progression) often complicate the swollen joint assessment of rheumatoid patients. 
Neither should be counted as joint swelling, but both can be present along with joint 
swelling, making this assessment more complicated than it might seem. Also, RA patients 
with longstanding disease often develop pannus formation, a fibrous tissue that is the 
result of prolonged inflammation inside the joint but that does not mean active disease 
per se and should not be accounted for in assessing swollen joints, which is sometimes 
difficult. 
Joint tenderness should be assessed by applying a pressure of 4Kg/cm2 (usually 
considered when the nail bed of the assessor becomes white) to each joint and evaluate 
the patient’s reaction for pain. However, this cannot be done in every joint, as in deeper 
joints like the hip or shoulder, where active and passive movement should help determine 
tenderness[10]. Importantly, RA patients frequently have other comorbidities, including 
chronic pain conditions such as fibromyalgia. These patients present a challenge for the 
assisting rheumatologist, as there will be an overestimation of tender versus swollen joints 
(on average ≥7 of the former) – determining the so-called “Fibromyalgic Rheumatoid”, a 
subset associated with higher levels of disability and disease activity scores and with a 
reduction in quality of life, while showing low swollen joint counts and inflammatory 
markers[11]. This results in misleadingly high DAS28 scores and often in unnecessary 
therapy escalation[12]. On the opposite end, there is the situation typical of earlier disease 
in which joint inflammation is sometimes painless and silent to palpation, although there 
is already histological and imaging proof of synovitis, which is associated with future 
bone damage and erosions. Thus, the joint count method is actually only a surrogate of 
inflammation in the joint and might not perform similarly in different phases of the 
disease[13]. Finally, there is also a “floor effect“ for joint counts, where in low disease 
activity states joint counts are low and the potential for detecting a change is smaller 
compared to patients with active disease[12].    
It is clear thus that joint counts face several challenges. In order to reduce this 
variability, a study assessed the effectiveness of a training procedure to standardize the 
28 joint count across assessors[14]. The authors found a considerable decrease in inter-
observer variation, mainly regarding the swollen joints (mean variation coefficient was 
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(41%) and swollen joints (32%). Even though training is effective, the inter-observer 
variability is still significant, and joint counts are overall not very well reproducible, 
requiring the same observer to evaluate patients in each serial visit in an optimal 
setting[15]. This poses a problem as it is usually not feasible to have the same assessor in 
every evaluation.  
In summary, joint counts represent a central tool in assessing disease activity of 
RA patients that correlates with patient prognosis and mortality[16] and cannot be 
replaced solely by self-assessment methods, as these have been demonstrated to correlate 
poorly with physician assessment of synovitis and swollen joints[17,18]. However, they 
present several challenges for the rheumatologists in clinical practice and do not reflect 
joint damage progression and disability[19]. In fact, they can be a source of time 
consumption in clinical visits and they have been shown to be neglected in most patient 
visits[20]. Moreover, training status and experience of the clinician assessing the joints is 
an important factor that should be taken into account. 
We hypothesize that joint counts are influenced by the training level of the 
clinician, being less variable and more consistent with other disease activity parameters 
for experienced consultants. Furthermore, we hypothesize the impact of clinical 
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2 – Aims 
 
Our main objective was to identify variables influencing the 28-joint counts in RA 
patients evaluated on standard clinical practice. In particular, we aimed to assess if there 
was a significant difference in the assessment of tender/swollen joints according to the 
physician’s experience (Rheumatology consultant vs. registrar) and number of years in 
training. Moreover, we would like to determine the inter- and intra-observer variation and 
if the joint counts are influenced by other factors such as: other disease activity-related 
variables (such as global patient VAS, ESR, CRP, DAS28), gender, age, disease duration, 
serological status for rheumatoid factor (RF) and anti-citrullinated protein antibodies 
(ACPA) and concurrent therapy (glucocorticoids, synthetic and biologic disease 
modifying anti-rheumatic drugs [DMARDs]). 
 
3 – Methods 
 
We used data from the Rheumatic Diseases Portuguese Register, Reuma.pt, 
concerning the RA patients treated with biologicals at the Rheumatology and Metabolic 
Bone Diseases Department of Hospital de Santa Maria, Centro Hospitalar Lisboa Norte. 
In our Department, these patients are followed in the setting of a day hospital, where 
treatment efficacy and safety are continuously evaluated and decisions on 
maintaining/changing treatment are taken. This constitutes the ideal situation for a study 
like the present one, as patients are evaluated by different rheumatologists, consultants or 
trainees, on different consecutive visits, thus enabling for comparison of joint counts in 
separate observations of the same patient and also between different patients. 
For this purpose, we analyzed data of all RA patients treated with any biologic 
DMARD at our Department from January 2014 to July 2016. We considered this 
timeframe expecting to have a significant pool of data on joint counts performed by 
different physicians with several levels of training. More specifically, we assessed each 
patient’s visit information regarding the following variables: patients and disease 
characteristics (age, gender, disease duration and seropositivity for RF and/or ACPA 
status); tender joint count (28 joints – tjc28), swollen joint count (28 joints – sjc28), ESR, 
patient global VAS (in a scale from 0 to 100 mm), physician VAS; biologic therapy, 
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golimumab, infliximab), tocilizumab (interleukin [IL]-6 receptor antagonist), rituximab 
(anti-CD20, B cell depleting agent) and abatacept (anti-CD80/86 fusion protein that 
targets T cell activation by inhibiting antigen presenting cell-mediated co-stimulation); 
current synthetic DMARDs, including methotrexate, sulfasalazine, hydroxychloroquine, 
leflunomide, azathioprine and cyclosporine; physician’s training status (consultant vs. 
registrar) and years of experience since beginning of Rheumatology training (in groups 
of 2 years –  from less than 2 to over 22 years – as we hypothesize that the first years of 
practice account for a great amount of variation in joint counts, thus deserving a special 
attention). We only included the physicians that, during the study period, were always 
registrars or consultants, thus excluding those that changed physician category during the 
study period. 
 In the analysis, our dependent variables are the number of tender and swollen 
joints out of a 28-joint count and the predictors are all other variables listed above. We 
set as continuous variables the patient’s age, disease duration, tender and swollen joint 
counts, ESR, patient global VAS, physician VAS, physician’s years of experience and 
biologic treatment duration; as categorical variables we considered gender, autoantibody 
status, physician’s years of experience in categories, monotherapy and biologic drug 
class. We defined the continuous variables as mean ± standard deviation (S.D.) and the 
discrete variables as absolute and relative frequencies. We conducted a univariate analysis 
to compare differences in disease activity parameters (tjc28, sjc28, patient global VAS, 
physician VAS and ESR) in visits conducted by registrars or consultants, using the 
Student’s T-test. To study the influence of each independent variable in the tender and 
swollen joint counts, we conducted a multivariate analysis, by applying a linear mixed 
model. In this model, the variables could either have a so-called “fixed effect” (like age 
and gender), where we are interested in their specific value (e.g. 54 years and female), or 
a “random effect” (like the patient and physician), considering that the model assumes 
that their effect on tjc28 and sjc28 has a normal distribution with mean zero and a standard 
deviation to be estimated. In addition, the model has an error term, which again is 
assumed to be normally distributed with mean zero and standard deviation to be 
estimated. This last term incorporates all effects and contributions that are not captured 
in the other terms of the model and that are assumed to be unbiased (thus, the mean of the 
distribution for the error term is zero). Also important to mention is the fact that each 
variable comes into the model in an additive (or linear) way. As such, by using a simple 
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Taking the age and gender as examples, the model estimates the same effect of age for 
both genders, instead of estimating if there is a different effect of age for male and female. 
What this means is that we’re using a regression model that will estimate the tender and 
swollen joint counts expressed through this equation:  
 
𝑡𝑗𝑐28 𝑜𝑟 𝑠𝑗𝑐28
= 𝑚𝑒𝑎𝑛 + 𝑎𝑔𝑒 (𝑓𝑖𝑥𝑒𝑑 𝑐𝑜𝑛𝑡𝑖𝑛𝑢𝑜𝑢𝑠) + 𝑔𝑒𝑛𝑑𝑒𝑟 (𝑓𝑖𝑥𝑒𝑑 𝑑𝑖𝑠𝑐𝑟𝑒𝑡𝑒)
+ 𝑝ℎ𝑦𝑠𝑖𝑐𝑖𝑎𝑛 𝑡𝑟𝑎𝑖𝑛𝑖𝑛𝑔 𝑠𝑡𝑎𝑡𝑢𝑠 (𝑓𝑖𝑥𝑒𝑑 𝑑𝑖𝑠𝑐𝑟𝑒𝑡𝑒) + (… )
+ 𝑝𝑎𝑡𝑖𝑒𝑛𝑡 (𝑟𝑎𝑛𝑑𝑜𝑚 𝑒𝑓𝑓𝑒𝑐𝑡) + 𝑝ℎ𝑦𝑠𝑖𝑐𝑖𝑎𝑛 (𝑟𝑎𝑛𝑑𝑜𝑚 𝑒𝑓𝑓𝑒𝑐𝑡) + 𝑒𝑟𝑟𝑜𝑟 
Equation 1 - Linear model estimating the tender/swollen joint count 
 
We used the SPSS Statistics, version 23.0.0.0 as our statistical analysis software, 
and the level of significance was considered at less than 0.05 (confidence interval of 
95%). 
 
4 – Results 
 
   4.1 - Sample characterization and descriptive analysis 
 
We included 260 patients, who were evaluated in a total of 3127 consecutive visits, 
with a mean number of 12 visits per patient.  
The patients’ characteristics are described in Table 1. This is a standard population 
of established RA with the majority of patients (88.1%) being female, with a mean age of 
56 years and 7 months, and a mean disease duration of 13 years and 8 months. One 
hundred and ninety-four patients (79.2%) were positive for RF and/or ACPA. 
 
Table 1 - Patient sample characteristics 
Variable Total (n = 260) 
Age, mean (S.D.), years* 56.6 (12.0) 
Gender - female, n (%) 229 (88.1) 
Disease Duration, mean (S.D.), years* 13.7 (9.4) 
RF and/or ACPA positive, n (%) 194 (79.2) 
*at time of first visit considered 
 
The disease activity parameters in each patient’s visit (n = 3127) are described in 
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joints. We found that in 44.3% and 12.6% of the visits, the patients had 0 or 1 tender 
joints, respectively (i.e. in over 50% of the patients’ visits, there were 1 or less tender 
joints; Figure 1). In 25.6% of the visits, the number of tender joints ranged from 2 to 5. 
The mean number of swollen joints per visit was 1.9 ± 3.3. In 53.6% of the patients’ visits, 
there were 0 swollen joints, while in 13.0% there was one (Figure 2). In 22.7% of the 
visits, the number of swollen joints ranged from 2 to 5. The mean patient global VAS was 
of 45 mm, and the most frequent referred value was 50 mm (19.3% of the patients’ visits). 
The mean physician’s VAS was 31.4 mm, and 20 mm was the most frequent value (given 
in 15.8% of the visits). At last, regarding the DAS28, a minimum of 0.5 and maximum of 
8.7 with a mean value of 3.3 ± 1.4 was seen. By grouping the DAS28 values into 
categories (Figure 3), we can see that in most of the visits, the patients had moderate RA 
activity (36.4%). Patients presented in remission in a significant proportion of visits 
(35.7%). In 16.6% of the visits, patients had low disease activity and only in 11.3% of the 
visits the disease was highly active.   
 
Table 2 - Disease activity parameters across visits assessed 
Variable Total (n = 3127) 
Tender joint count (0-28), mean (S.D.) 2.9 (4.8) 
Swollen joint count (0-28), mean (S.D.) 1.9 (3.3) 
Patient Global VAS, mean (S.D.), mm 45.0 (23.9) 
Physician VAS, mean (S.D.), mm 31.4 (21.9) 
DAS28, mean (S.D.) 3.3 (1.4) 
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Figure 2 - Proportion of swollen joint counts groups across study visits 
 
Figure 3 - Distribution of DAS28 activity class across patient visits 
 
Regarding the physicians, this group included 26 observers, out of which 13 were 
registrars and 13 consultants. Physicians experience at time of visit ranged from 7 days 
to 22 years of practice. The mean time of experience across visits was 7.6 ± 6.8 years. 
Figure 4 shows that a significant number of visits (35.5%) was conducted by physicians 
with only 2 or less years of experience, but there was also a considerable proportion of 
visits (20.8%) with physicians with 10 to 12 years of experience. The third most prevalent 
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as registrars and which accounted for 10.8% of the visits. Mean time since the beginning 
of training was 1.4 ± 1.0 years for registrars and 13.0 ± 4.8 years for consultants (Figure 
5).  
 
Figure 4 - Physicians' years of experience at the time of visit expressed in categories 
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At last, focusing on the treatment for RA in each patient’s visit (Table 3), we can 
state that in most of them (68.7%), the patients were doing combination therapy with 
synthetic DMARDs on top of biologics. In 2373 patients’ visits (75.9% of the total), they 
were taking at least one synthetic DMARD. The mean number of active synthetic 
DMARDs was 0.9 ± 0.7, and it varied between 0 drugs (in 24.1% of the total of patients’ 
visits) and 3 drugs (2.8% of the visits). The most common synthetic DMARD was 
methotrexate, taken by patients in 2009 visits (64.2%). In 2312 visits (73.9%) patients 
were taking corticosteroids. Finally, regarding the biologics (Figure 6), in most of the 
visits, the patients were on anti-TNF therapy (50.4%) and in a significant proportion of 
visits (39.0%), they were being treated with tocilizumab or rituximab. Only in 9.3% of 
the visits, patients were not on any biologic therapy. 
Table 3 - Rheumatoid arthritis treatment taken by patients in each visit 
Variable Total (n = 3127) 
Biologic + DMARD , n (%) 2147 (68.7) 
Biologic monotherapy, n (%) 690 (22.1) 
No biologic, n (%) 290 (9.3) 
DMARDS  
   Methotrexate, n (%) 2009 (64.2) 
   Sulfasalazine, n (%) 454 (14.5) 
   Hydroxychloroquine, n (%) 319 (10.2) 
   Leflunomide, n (%) 104 (3.3) 
   Azathioprine, n (%) 7 (0.2) 
   Cyclosporine, n (%) 16 (0.5) 
Corticosteroids, n (%) 2312 (73.9) 
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4.2 - Comparison of disease activity parameters assessed by registrars 
and consultants 
 
The values of disease activity parameters determined in visits performed by 
registrars and consultants are summarized in Table 4. 
We can see that both the swollen joint counts and the physician VAS are 
significantly different in each group, with the consultants measuring a higher mean count 
of swollen joints (2.0 ± 3.7 vs 1.6 ± 2.8) but registering lower mean VAS values (28.4 
mm vs 34.3 mm) than the registrars. The other three disease activity parameters didn’t 
show any statistically significant difference between the registrars and the consultants. 
 
Table 4 - T-test results regarding the differences between registrars and consultants in the disease activity 
parameters 
Variable Registrars Consultants P-value 
Tender joint counts, 
mean (S.D.) 
2.9 (4.3) 3.0 (5.2) 0.559 
Swollen joint counts, 
mean (S.D.) 
1.6 (2.8) 2.0 (3.7) 0.001 
Patient global VAS, 
mean (S.D.), mm 
45.8 (23.5) 44.4 (24.2) 0.140 
Physician VAS, mean 
(S.D.), mm 
34.3 (22.0) 28.4 (21.4) <0.001 
ESR, mean (S.D.) 21.9 (20.0) 22.3 (20.4) 0.584 




4.3 - Variables influencing tender and swollen joint counts 
 
We considered the following 12 variables as potentially influencing the joint 
counts: patient age, gender, disease duration, RF/ACPA status, ESR, patient global VAS, 
monotherapy, biologic drug class, biologic treatment duration, physician VAS, physician 
years of experience, and physician training status (registrar vs. consultant). 
Regarding the tender joint counts, we found that the model that best explained this 
dependent variable was the one that included 11 of the variables above mentioned, 
excluding the physician years of experience (Table 5). The only significant independent 
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VAS and biologic treatment duration. The estimated effect of each variable and respective 
p-value is described in Table 5.  
We found that the patient’s age has a significant effect in the number of tender 
joints (thus the latter being higher in older patients), more specifically increasing by 1 
tender joint for every additional 25 years. Female patients had a trend towards a higher 
number of tender joints compared to males, by approximately 1. Longer disease duration, 
however, was found to negatively influence the tender joint count, decreasing it by 1 for 
every 16 years and 7 months of disease. Not surprisingly, the patient global VAS had a 
significant effect in determining the tcj28, increasing it by 1 for every 50 mm increment 
in VAS. In line with this, the physician’s VAS was the most important predictor of tjc28, 
increasing it by 1 for only 11 mm increment in the scale (P-value < 0.001). Regarding 
treatment, even though the number of drugs and the biologic drug class weren’t 
significantly associated with tender joint counts, there was a negative association with 
biologic treatment duration (P-value = 0.039), with an estimated effect of decreasing the 
tjc28 by 1 for every 8 years and 3 months of treatment. Finally, the training status 
(registrar/consultant) was not independently associated with the tjc28, when accounting 
for all the remaining variables (P-value = 0.786). Even though it is not represented in the 
final model, similar results were found with physician’s years of experience as a 
continuous or categorical variable (P-value > 0.05). 
Of note, the inter-observer’s variability effect was significant and estimated to be 
of 1.20 (P-value = 0.003), which means that the tjc28 value can be up to 1.20 higher or 
lower than the average estimated value (based on all the other variables). It also indicates 
there are probably unmeasured variables that could explain this effect. Also, the patient’s 
variability effect was highly significant and estimated at 1.79 (P-value < 0.001), which 
means that in our patient sample, the tjc28 can vary by almost 2 due to a patient “random” 
effect, which is considered random because the unmeasured variables’ effect that could 
explain this variation is unknown. The model’s error variability was 3.33, which means 
that there can be a variation of up to 3.33 in the tender joint counts that cannot be 
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Table 5 - Linear mixed model's prediction of 28 tender joint count: independent variables' effect in tender joint 
counts 
Variable ß-coefficient; p-value 
Age 0.04; 0.005 
Gender, female sex 0.91; 0.054 
Disease Duration -0.06; 0.001 
RF and ACPA negative -0.01; 0.974 
ESR 0.01; 0.262 
Patient Global VAS 0.02; 0.003 
Physician VAS 0.09; <0.001 
Combination therapy 0.03; 0.954 
Biologic Drug Class  
   Anti-TNF 0.00; 1.000 
   Tocilizumab -0.30; 0.812 
   Rituximab 0.53; 0.683 
   Abatacept . 
Biologic drug duration (months) -0.01; 0.039 
Physician training status, registrar 0.14; 0.786 
P-Values below 0.05 are shown in bold 
 
 
Regarding the swollen joint counts, there were 4 variables that were neither 
significant nor contributed to better explain the number of swollen joints – the patient’s 
age, gender, monotherapy/combination therapy and physician’s years of experience. As 
such, only the other 7 variables were included in the model, and out of these, only the 
patient global VAS, physician’s VAS, disease duration and biologic treatment duration 
were independently associated with the sjc28 (Table 6). How each variable affects the 
number of swollen joints and their respective level of significance is depicted in Table 6.  
The patient global VAS’ effect in swollen joint counts was statistically significant 
(P-value = 0.012) although unlikely to be clinically relevant, as it was estimated to be a 
decrease of 1 swollen joint per 100 mm reduction in the global VAS. Higher duration of 
disease and biologic treatment were associated with lower sjc28, with a decrease in 1 
swollen joint for every 33 years and 6 months of disease and for every 8 years and 3 
months of biologic therapy, respectively. The physician VAS was a significant predictor 
(P-value < 0.001) of the sjc28, with one additional swollen joint counted for every 12,5 
mm increase in the scale. Finally, as for the tjc28, the registrar/consultant status was not 
significantly associated with sjc28 and neither were the physician’s years of experience 
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Of note, the inter-observer’s variability effect was estimated to be of 0.99 (P-value 
= 0.003), which means that the sjc28 value can be significantly up to 1 joint higher or 
lower than the average estimated due to a physician “random” effect. Once again, it 
indicates there are probably unmeasured explanatory variables for this effect. The 
patient’s variability effect was of 1.04 (P-value < 0.001), which means that in our patient 
sample, the sjc28 can vary by around 1 count due to a patient “random” effect. The 
model’s error variability accounted for 2.33, meaning that there is about a 2.33 variation 
in the swollen joint count that the model can’t explain only with the variables we used.  
  
Table 6 - Linear mixed model's prediction of sj28: independent variables' effect in swollen joint counts 
Variable Effect in sjc28; p-value 
Disease Duration -0.03; 0.014 
RF and ACPA negative 0.37; 0.165 
ESR 0.01; 0.059 
Patient Global VAS -0.01; 0.012 
Physician VAS 0.08; <0.001 
Biologic Drug Class  
   Anti-TNF -0.36; 0.640 
   Tocilizumab 0.06; 0.938 
   Rituximab -0.29; 0.726 
   Abatacept . 
Biologic drug duration (months) -0.01; 0.009 
Physician training status, registrar -0.19; 0.656 
P-Values below 0.05 are shown in bold 
 
 
5 – Discussion 
 
In this study, we hypothesized if the physician training status had an impact on the 
tender and swollen joint counts, and we found that – on average and in different visits 
with different patients – consultants counted significantly more swollen joints than 
registrars, but a similar number of tender joints. However, when we accounted for the 
effect of other variables in a multivariate model, as well as the patient and physician error, 
we failed to confirm this finding, as neither tender nor swollen joints were significantly 
associated with the training status (registrars vs. consultants). Moreover, we also failed 
to confirm what we had initially proposed: that the years of experience since the 
beginning of rheumatology training had an impact on joint counts. However, the inter-
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confirming that there are other variables not considered in the model that can explain 
some variability in joint counts when performed by different assessors. It is also important 
to mention the patient variability, which in both the tender and swollen joint assessments 
was significant, indicating that perhaps some patient comorbidities – such as depression 
and fibromyalgia – could be variables of interest to explain these differences. 
Unfortunately, we were not able to confirm this due to a significant amount of missing 
data on these variables that would limit the construction of a multivariate model. 
Several variables did influence the tender joint counts though, the most important 
and significant (P-value < 0.001) of which was the physician VAS, followed by the 
disease duration, patient age and patient global VAS. This reveals the great influence that 
other disease parameters (physician VAS, patient global VAS and disease duration) have 
on the tjc28, which corroborates the fact that this variable is indeed adequate to measure 
the RA activity. The evaluating physician plays a great role in the joint counts, as his 
global impression of disease is strongly and positively influenced by the number of tender 
joints assessed. 
Concerning the swollen joints, once again, the most important and significant 
predictor (P-value < 0.001) was the physician VAS, followed by the patient global VAS, 
disease duration and biologic treatment duration. However, in opposition to what we had 
found regarding the tjc28, the patient’s age was not significantly associated with swollen 
joints assessed. This can result from the fact that assessing a swollen joint is actually a 
less patient-dependent activity compared to tender joint assessment, with the main role 
being performed by the physician himself. According to this, even though the patient 
VAS was independently and positively associated with swollen joint counts, its overall 
impact was low. Also interesting to note is that the biologic treatment duration had the 
very same impact in both the tender and swollen joint counts. Just like what we had 
observed with the tjc28, these data confirm the importance of sjc28 in the clinical 
assessment of RA activity. The physician role seems to be the most important, as the 
physician VAS is strongly influenced by the swollen joint counts and accounts for the 
greatest increase in sjc28. 
The main limitation of this study is the fact that we did not manage to fully exclude 
the actual variation in disease activity as a confounding factor accounting for the tender 
and swollen joint count variability. Even though the study period is not too long (from 
January 2014 to July 2016), change in disease activity over time is still expected, which 
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We tried to address this by using a linear mixed model but we acknowledge that the ideal 
setting to answer the question we were proposing would be to have a simultaneous 
evaluation of the same patients by different physicians and then compare the joint counts 
across groups. Another limitation is that the statistical analysis model we used assumed 
that the error had a normal distribution and that the dependent variables – tjc28 and sjc28 
– were continuous variables (when they actually followed a Poisson distribution). Using 
a generalized mixed model would have allowed correcting for the latter inadequacy, but 
it would be too complex and long-taking, making it too hard to actually apply in this 
context. Yet another limitation concerning the model we used was that we did not 
consider the interactions between variables, because, unfortunately, there are too many 
possible interaction terms (even when just thinking of two-way interactions), and it is thus 
not feasible to estimate them in such a model. Also, we used the Student’s T-test to assess 
the differences in the tender and swollen joint counts in registrars vs. consultants, even 
though neither the tjc28 nor the sjc28 followed a normal distribution. A non-parametric 
test could have been used in this case, but considering the large number of visits (over 
3000) we considered it appropriate to apply the Student’s T-test. Finally, another 
limitation was related to the fact that, even though there were some variables – such as 
erosive/non-erosive disease, smoking status, body mass index, CRP, patient pain VAS, 
health-assessment questionnaire (HAQ) disability index, previous biologic therapy, 
current glucocorticoids and NSAIDs, comorbidities such as fibromyalgia, depression, 
anxiety (or concurrent medication for these conditions) – that could be of value to explain 
the variation in tjc28 and sjc28, we had to exclude them, due to the impracticability of 
analyzing every possible variable in one study, and also considering that some of them 
had a great number of missings (namely patient pain VAS, HAQ disability index, and 
comorbidities such as fibromyalgia). 
In conclusion, in a real-life setting, the variables that mostly affect the tender and 
swollen joint counts are other disease-related parameters (mainly patient global VAS, 
physician VAS and disease duration) and overall there does not seem to be a significant 
difference in the assessment of tender and swollen joints between registrars and 
consultants. Moreover, physician years of experience also do not seem to have an 
independent effect in joint counts, but there is still a high inter-assessor and inter-patient 
variability, which can be further investigated in future studies with a different design, 
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8 – Appendix 
 
Resumo do projecto: 
Variabilidade das contagens articulares em doentes com Artrite 
Reumatóide seguidos na prática clínica 
 
A Artrite Reumatóide (AR) é uma doença inflamatória sistémica caracterizada 
pelo envolvimento articular com destruição progressiva das articulações. As principais 
manifestações clínicas são a dor e tumefacção articulares, sendo que esta última indica a 
existência de sinovite.  
O método das contagens articulares, que avalia a existência de articulações 
dolorosas e tumefactas, é utilizado na avaliação clínica dos doentes com AR, uma vez 
que se correlaciona com a mortalidade e prognóstico da mesma. Como tal, pretende-se 
que este parâmetro seja o mais objectivo possível, com pouca ou nenhuma variabilidade 
inter e intra-observador. As contagens articulares, juntamente com a escala visual 
analógica (EVA) global do doente, EVA do médico, a velocidade de sedimentação (VS), 
e a proteína C-reactiva (PCR), integram o disease activity socre 28 (DAS28), que é 
utilizado na prática clínica não só para avaliar a actividade da doença, mas também para 
ajudar na decisão terapêutica. Assim, um score < 2,6 indica remissão da doença; < 3,2 
baixa actividade e > 5,1 doença activa. 
Existem vários métodos de contagens articulares, incluindo o que avalia 36, 44, 
46 e até 66/68 articulações, mas o mais usado é sem dúvida o de 28 articulações, uma vez 
que não só foi comprovado não ser inferior aos outros, mas também é o mais simples e 
prático. Todavia, este apresenta limitações como o facto de não incluir as articulações dos 
pés, criando assim uma falha importante relativa aos doentes com envolvimento particular 
destas articulações, que podem ter doença activa, mas cujo DAS28 não vai permitir 
detectar.  
A não esquecer ainda, temos a própria variabilidade entre médicos, que se justifica 
com o facto de cada avaliador ter os seus métodos e experiência pessoais que irão ser 
determinantes na forma como as contagens articulares são feitas. Também o mesmo 
observador pode avaliar de formas diferentes o mesmo doente em consultas consecutivas, 
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A complicar a avaliação das articulações tumefactas, temos o edema ósseo e 
deformidades articulares, que, embora não devam ser consideradas como tumefacção 
articular, são facilmente confundíveis como tal. Existe ainda a formação do “pannus” 
(resultante de inflamação com produção de tecido fibroso) aquando de uma duração 
prolongada de doença que se assume como factor de confusão na avaliação das 
articulações tumefactas, pese embora este por si não signifique doença activa. 
Na avaliação das articulações dolorosas, a presença de comorbilidades como a dor 
crónica (p.e. fibromialgia) representam um desafio, pois conduzem a uma sobrestimação 
(em média de 7 articulações dolorosas a mais, em comparação com as tumefactas) das 
contagens articulares, representando este subgrupo de doentes um com scores de 
actividade da doença demasiado elevados e baixa qualidade de vida, apesar do reduzido 
número de articulações tumefactas e de valores dos marcadores de inflamação. Isto 
culmina em valores de DAS28 irrealisticamente elevados e escalada terapêutica 
desnecessária. No extremo oposto, temos os doentes em fase inicial de doença, que, como 
tal, são clinicamente silenciosos, apesar das evidências histológica e imagiológica de 
doença activa e que poderá evoluir para dano e erosão ósseos. Para concluir, existe uma 
variedade de factores que complicam o método das contagens articulares e que o tornam 
num desafio clínico diário, o que é de todo indesejável, dada a elevada importância clínica 
que assume. 
Assim sendo, este projecto teve como objectivo o estudo da variabilidade nas 
contagens das articulações dolorosas e tumefactas em doentes com AR avaliados na 
prática clínica habitual. Com esta ideia em mente, pretendemos verificar o efeito dos anos 
de experiência do médico e respectivo grau de especialidade (interno ou especialista) nas 
contagens articulares, e identificar as variáveis que as possam influenciar. 
Para tal, usámos os dados do Registo Nacional de Doenças Reumáticas – Reuma.pt 
– que contém as informações relativas aos doentes com AR e que estão a fazer terapêutica 
biológica no Departamento de Reumatologia e Doenças Ósseas Metabólicas do Hospital 
de Santa Maria, Centro Hospitalar Lisboa Norte. A janela temporal a que o nosso estudo 
se refere é de Janeiro de 2014 a Julho de 2016, e foram avaliadas 3127 consultas relativas 
a 260 doentes diferentes e 26 médicos diferentes. As variáveis que trabalhámos foram as 
seguintes: sexo e idade do doente, duração da doença, seropositividade para factor 
reumatóide (FR) e/ou anticorpos anti-péptidos citrulinados (AAPC); contagens de 
articulações dolorosas (num total de 28), contagens de articulações tumefactas (num total 
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(fármacos modificadores da doença para a AR), grau de especialidade do médico (interno 
vs. especialista) e anos de experiência desde o início do internato em Reumatologia. 
Começámos por fazer uma análise descritiva das variáveis, definindo as contínuas como 
média ± desvio padrão, e as discretas como frequência absolutas e relativas. 
Posteriormente, fizemos uma análise univariada com o teste T-Student para verificar as 
diferenças nos parâmetros de actividade da doença (articulações dolorosas, articulações 
tumefactas, EVA doente, EVA médico e VS) das consultas dadas por internos vs. 
especialistas. Finalmente, fizemos uma análise multivariada para estudar o efeito 
individual de cada variável independente nas contagens de articulações dolorosas e 
tumefactas, usando para tal um modelo linear misto. 
Dos 260 doentes incluídos, 88,1% eram do sexo feminino com média de idades de 
56 anos e 7 meses e duração média da doença de 13 anos e 8 meses. Setenta e nove por 
cento dos doentes eram seropositivos para FR ou AAPC. O número médio de articulações 
dolorosas avaliado foi de 2,9 ± 4,8, e em mais de 50% das consultas, os doentes tinham 
uma ou zero articulações dolorosas. O número médio de articulações tumefactas foi de 
1,9 ± 3,3, e em mais de 50% das consultas foram contabilizadas zero articulações 
tumefactas. O EVA médio dos doentes foi de 45,0 mm, e o dos médicos 31,4 mm. Quanto 
ao DAS28, o valor médio foi de 3,3 ± 1,4. Agrupando os valores de DAS28 por 
categorias, percebemos que, em 36,4% das consultas, os doentes tinham actividade 
moderada da doença e, em 35,7% delas, estavam em remissão. Relativamente aos 
médicos, houve 13 internos e 13 especialistas, e o tempo médio de experiência dos mesmo 
ao longo das consultas foi de 7,6 ± 6,8 anos. Em 35,5% das consultas, eles tinham menos 
de 2 anos de experiência, e em 20,8% delas, tinham 10 a 12. Finalmente, no que toca à 
terapêutica, na maioria das consultas (68,7%), os doentes estavam a fazer terapêutica 
biológica combinada com DMARDs. O número de DMARDs médio foi de 0,9 ± 0,7 e na 
maioria das consultas (75,9%), os doentes estavam a tomar pelo menos um fármaco desta 
classe, sendo o metotrexato o fármaco mais comum (activo em 64,2% das consultas). 
Quanto à corticoterapia, os doentes estavam sob corticosteróides em 73,9% das consultas. 
Por fim, mencionando os biológicos, a terapêutica anti-TNF foi observada em 50,4% das 
consultas, sendo seguida pelo uso de tocilizumab ou rituximab, o que se verificou em 
39,0% dos casos. 
Relativamente às diferenças entre internos e especialistas em termos de avaliação 
de parâmetros de actividade da doença, observámos que os especialistas contabilizam em 
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internos (2,0 ± 3,7 vs. 1,6 ± 2,8, respectivamente; Valor-P = 0,001), ainda que registem 
valores de EVA mais baixos (28,4 mm vs. 34,3 mm, respectivamente; Valor-P < 0,001). 
Não houve diferença significativa nos restantes parâmetros da doença, incluindo as 
contagens de articulações dolorosas (3,0 ± 5,2 nos especialistas vs. 2,9 ± 4,3 nos internos; 
Valor-P = 0,559)  
Por fim, quanto à análise multivariada, foram estudadas as seguintes variáveis: 
sexo e idade do doente, duração da doença, seropositividade, EVA doente, EVA médico, 
anos de experiência do médico, grau do médico (interno ou especialista), VS, 
monoterapia, classe do biológico e duração do biológico. Quanto ao modelo que melhor 
explicou as contagens de articulações dolorosas, este incluiu todas as variáveis 
supramencionadas, com excepção dos anos de experiência do médico. Tanto a idade 
como a EVA global do doente, EVA do médico, a duração da doença e duração do 
tratamento com biológicos revelaram ser variáveis significativamente associadas às 
contagens de articulações dolorosas, sendo que as duas últimas variáveis estão associadas 
a uma diminuição das contagens de articulações dolorosas, enquanto as três primeiras a 
um aumento. De notar que não houve diferenças significativas entre os internos e 
especialistas, nem os anos de experiência tiveram influência significativa (Valor-P > 
0,05) nas contagens de articulações dolorosas. Todavia, a variabilidade inter-observador 
foi significativa e teve o valor de 1,20 (Valor-P = 0,003), o que indica que pode haver 
uma variação do número de articulações dolorosas até 1,2 superior ou inferior ao valor 
médio estimado com base em todas as restantes variáveis. A variabilidade devido ao 
doente foi também ela significativa (Valor-P < 0,001) e no valor de 1,79, o que se fica a 
dever ao efeito de variáveis não consideradas no estudo. Em relação ao modelo das 
contagens de articulações tumefactas, nem a idade nem sexo do doente, nem as variáveis 
monoterapia/terapêutica combinada ou os anos de experiência do médico foram incluídas, 
dado não contribuírem para explicar a variação das contagens de articulações tumefactas. 
Para além disso, apenas a EVA global do doente, EVA do médico, duração da doença e 
duração do tratamento com biológicos revelaram ser variáveis estatisticamente 
significativas. Destas, apenas a EVA do médico estava associada a um aumento da 
contagem de articulações tumefactas (de 1 articulação por cada aumento de 12,5 mm na 
escala (Valor-P < 0,001)), enquanto as restantes 3 variáveis estavam associadas a uma 
diminuição da contagem articular. Mais uma vez, nem o grau de especialidade do médico, 
nem os seus anos de experiência tiveram qualquer impacto na contagem de articulações 
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doentes (0,99 e 1,04, respectivamente; Valores-P de 0,003 e < 0,001, respectivamente) 
foram significativas, o que corrobora a existência de outras variáveis não medidas neste 
estudo que poderiam explicar este efeito. 
A principal limitação deste estudo foi o facto de não termos conseguido excluir a 
variação da actividade da doença como um factor confundidor na estimação dos efeitos 
de cada variável independente sobre as contagens articulares. Usámos o modelo linear 
misto que incluiu os parâmetros da actividade da doença numa tentativa de contornar esta 
limitação, mas reconhecemos que o ideal teria sido os mesmo doentes terem sido 
avaliados na mesma data por médicos diferentes. Relativamente ao modelo linear misto 
que usámos, o facto de este assumir que a distribuição do erro era normal e o facto de não 
termos considerado as interações entre as variáveis também se assumiram como 
limitações. Em relação ao teste T-Student, este assume que as distribuições das contagens 
articulares eram normais (o que não corresponde à realidade), o que, por sua vez, 
constituiu mais uma limitação. Por fim, tivemos de excluir várias variáveis do nosso 
estudo (como estado erosivo da doença, Índice de massa corporal do doente, 
comorbilidades como depressão e fibromialgia, entre outros), o que se ficou a dever não 
só à existência de vários missings, mas também à inexequibilidade de uma análise tão 
morosa que integrasse todas as variáveis. 
Em conclusão, podemos afirmar que nem o grau de treino do médico nem os anos 
de experiência têm um impacto significativo nas contagens de articulações dolorosas ou 
tumefactas, sendo estas especialmente determinadas pelos parâmetros relacionados com 
a doença – nomeadamente a EVA global do doente, EVA do médico e duração da doença. 
Esta observação vem reforçar a pertinência das contagens na avaliação da actividade da 
AR. Por outro lado, é de realçar o facto das variabilidades entre observadores e devida ao 
doente serem significativas, o que nos leva a supor que talvez outros factores como 
comorbilidades do doente (depressão e/ou fibromialgia) possam ser variáveis importantes 
a considerar em estudos futuros em que se dê prioridade à avaliação simultânea dos 
mesmos doentes por diferentes médicos. 
  
 
 
